Compare Okta, Inc. (OKTA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Okta, Inc. trades at $173.5 (market cap $29.30B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.6× Okta, Inc.'s market cap, and Okta, Inc. is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| OKTA | VRTX | |
|---|---|---|
Market Cap | $29.30B | $134.06B |
Sector | Technology | Health |
52-Week High | $173.04 | $557.96 |
52-Week Low | $62.93 | $376.62 |
Enterprise Value | $27.05B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Okta (OKTA) trades at $167.60, down 1.76% on the day, but remains up 94% year-to-date driven by strong earnings beats and AI-driven demand for cybersecurity. The stock exhibits a bullish technical trend, with moving averages signaling strength and key support at $166. Fundamentally, revenue grew to $2.61 billion in 2025 with a net income margin turning positive at 1.07%, while valuation ratios like P/E of 100.96 reflect high growth expectations. Recent news highlights AI security offerings boosting investor confidence.
Outlook is positive with a consensus price target of $181.61, indicating 8% upside, supported by 75% analyst buy ratings. Opportunities include expanding AI identity governance and enterprise adoption, but risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and integration challenges. Net cash flow turned positive in 2025, though debt-to-asset ratio improved to 9.09%.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
